Tang Han-Ning, Pan Bi-Hui, Wang Li, Zhu Hua-Yuan, Fan Lei, Xu Wei, Li Jian-Yong
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing 210029, China.
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing 210029, China.
Transl Oncol. 2021 Apr;14(4):101035. doi: 10.1016/j.tranon.2021.101035. Epub 2021 Feb 11.
Chronic lymphocytic leukaemia is one of the most common types of adult leukaemia. Cancer-related systemic inflammation response has been characterized to correlate with therapeutic outcome in patients with cancer. The C-reactive protein-to-albumin (CRP/ALB) ratio (CAR), which is an inflammatory marker, has been reported as a novel prognostic factor in several cancers. The aim of our study was to evaluate the prognostic value of the CAR in patients with chronic lymphocytic leukaemia (CLL). We retrospectively reviewed the clinical characteristics of 322 newly diagnosed CLL patients, investigated the correlations among pretreatment CAR, treatment-free survival (TFS) and overall survival (OS), assessed the prognostic effect of the CAR to compare with other inflammation-related prognostic index by the area under the curve (AUC), and combined CAR and CLL-international prognostic index (CLL-IPI) together to improve the current prognostic system. The results showed that CAR was an independent prognostic factor for OS. Furthermore, the predictive and discriminatory capacity of CLL-IPI together with CAR level was superior to that of CLL-IPI alone for OS. In conclusion, serum CRP and ALB levels are both simple and easily accessible parameters, whose ratio CAR may be good candidates for predicting prognosis in the future clinical practice of CLL.
慢性淋巴细胞白血病是成人白血病最常见的类型之一。癌症相关的全身炎症反应已被证实与癌症患者的治疗结果相关。C反应蛋白与白蛋白比值（CAR）作为一种炎症标志物，已被报道为多种癌症的新型预后因素。本研究的目的是评估CAR在慢性淋巴细胞白血病（CLL）患者中的预后价值。我们回顾性分析了322例新诊断CLL患者的临床特征，研究了治疗前CAR、无治疗生存期（TFS）和总生存期（OS）之间的相关性，通过曲线下面积（AUC）评估CAR与其他炎症相关预后指标相比的预后效果，并将CAR与CLL国际预后指数（CLL-IPI）相结合以改进当前的预后系统。结果显示，CAR是OS的独立预后因素。此外，CLL-IPI联合CAR水平对OS的预测和鉴别能力优于单独使用CLL-IPI。总之，血清CRP和ALB水平都是简单易获取的参数，其比值CAR可能是未来CLL临床实践中预测预后的良好指标。
